Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma

Modern Pathology

Volumn 19, Issue 9, 2006, Pages 1170-1180

  Winnepenninckx, Véronique ^a   Debiec Rychter, Maria ^a   Beliën, Jeroen A M ^b   Fiten, Pierre ^c   Michiels, Stefan ^d   Lazar, Vladimir ^d   Opdenakker, Ghislain ^c   Meijer, Gerrit A ^b   Spatz, Alain ^d   Van Den Oord, Joost J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Aneuploidy; hPTTG1; Melanoma; p53; Securin

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PROTEIN; PROTEIN P53; SECURIN; UNCLASSIFIED DRUG;

ANAPHASE; ANEUPLOIDY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMETRY; DENSITY; FEMALE; GENE EXPRESSION; GENOMIC INSTABILITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); NEVUS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CANCER; STATISTICAL SIGNIFICANCE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CHILD; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFANT; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS; POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747619825     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800627     Document Type: Article

References (40)

1. Pei L, Melmed S. Isolation and characterization of a pituitary transforming gene (PTTG). Mol Endocrinol 1997;11:433-441.
2. Zhang X, Horwitz GA, Prezant TR, et al. Sructure, expression and function of human pituitary tumor transforming gene (PTTG). Mol Endocrinol 1999;13:156-166.
3. Kakar SS, Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1), a novel gene in human tumorigenesis. Cytogenet Cell Genet 1999;84:211-216.
4. Yu R, Mehmed S. Pituitary transforming gene: an update. Front Horm Res 2004;32:175-185.
5. Saez C, Japon MA, Ramos-Morales F, et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 1999;18:5473-5476.
6. Ogbagabriel S, Fernando M, Waldman FM, et al. Securin is overexpressed in breast cancer. Mod Pathol 2005;18:985-990.
7. Honda S, Hayashi M, Kobayashi Y, et al. A role for the pituitary tumor-transforming gene in the genesis and progression of non-small cell lung carcinomas. Anticancer Res 2003;23:3775-3782.
8. Heaney AP, Singson R, Mc Cabe CJ, et al. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000;355:716-719.
9. Shibata Y, Haruki N, Kuwabara Y, et al. Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 2002;32:233-237.
10. Saez C, Pereda T, Borrero JJ, et al. Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene 2002;21:8173-8177.
11. Ishikawa H, Heaney AP, Yu R, et al. Human pituitary tumor transforming gene induces angiogenesis. J Clin Endocrinol Metab 2001;86:867-874.
12. Yu R, Lu W, Chen J, et al. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 2003;144:4991-4998.
13. Pei L. Identification of c-myc as a downstream target for pituitary tumor-transforming gene. J Biol Chem 2001;276:8484-8491.
14. Bernal JA, Luna R, Espina A, et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002;32:306-311.
15. Boelaert K, McCabe CJ, Tannahill LA, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003;88:2341-2347.
16. Solbach C, Roller M, Fellbaum C, et al. PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004;13:80-81.
17. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
18. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-482.
19. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005;46:481-489.
20. Ploeger LS, Belien JAM, Poulin NM, et al. Confocal 3D DNA cytometry: assessment of required coefficient of variation by computer simulation. Cell Oncol 2004;26:93-99.
21. Belien JAM, van Ginkel AH, Tekola P, et al. Confocal DNA cytometry: a contour-based segmentation algorithm for automated three-dimensional image segmentation. Cytometry 2002;49:12-21.
22. Zhou C, Liu S, Zhou X, et al. Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer 2005;113:891-898.
23. Hamid T, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer 2005;4:3.
24. Zou H, Mc Garry TJ, Bernal T, et al. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418-422.
25. Giatromanolaki A, Sivridis E, Kouskoukis C, et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 2003;13:493-501.
26. Treszl A, Adany R, Rakosy Z, et al. Extra copies of c-myc are more pronounced in nodular melanomas than in superficial spreading melanomas as revealed by fluorescence in situ hybridisation. Cytometry B 2004;60:37-46.
27. Poetsch M, Dittberner T, Woenckhaus C. Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin? Cell Mol Life Sci 2003;60:1923-1932.
28. De Wit PE, Kerstens HM, Poddighe PJ, et al. DNA in situ hybridization as a diagnostic tool in the discrimination of melanoma and Spitz naevus. J Pathol 1994;173:227-233.
29. Kanakis D, Kirches E, Mawrin C, et al. Promotor mutations are no major cause of PTTG overexpression in pituitary adenomas. Clin Endocrinol 2003;58:151-155.
30. Park KH, Choi SE, Eom M, et al. Downregulation of the anaphase-promoting complex (APC) 7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res 2005;7:238-247.
31. Wang Q, Moyret-Lalle C, Couzon F, et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 2003;22:1486-1490.
32. Chamaon K, Kirches E, Kanakis D, et al. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor I and insulin differs between malignant and non-neoplastic astrocytes. Biochem Biophys Res Comm 2005;331:86-92.
33. Satyamoorthy K, Li G, Vaidya B, et al. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001;61:7318-7324.
34. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-5083.
35. Wang H, Shen SS, Wang H, et al. Expression of IGFBP2 in melanocytic lesions. J Cutaneous Pathol 2003;30:599-605.
36. Kim D, Pemberton H, Stratford AL, et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 2005;24:4861-4866.
37. Margolis RL. Tetraploidy and tumor development. Cancer Cell 2005;8:353-354.
38. Mc Cabe CJ, Boelaert K, Tannahill LA, et al. Vascular endothelial growth factor, its receptor KDR/Flk-1 and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238-4244.
39. Boelaert K, Yu R, Tannahill LA, et al. PTTG's C-terminal PXXP motifs modulate critical cellular processes in vitro. J Mol Endocrinol 2004;33:663-677.
40. Hussein MR. The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? Tumour Biol 2004;25:200-207.